In 2025, biopharma therapeutics and platforms M&A rebounded strongly, driven by larger, high-value transactions rather than volume alone. The sector completed 109 deals totaling $140.9B, up from 101 deals and $61.8B in 2024, with average deal size rising to $1.3B. Cash-only value reached $119.1B, up 2.4 times versus 2024, while average and median upfronts increased to $1.9B and $591M, respectively, highlighting stronger pricing and broader market shifts toward higher-value, strategic acquisitions.
Healthcare M&A overall hit $269.3B, with Biopharma ($146.8B) and Diagnostics/Tools ($74.8B) leading growth, while Medtech cooled and Manufacturing Tech remained steady. Deal volume expanded 26% to 585 transactions, reflecting broad-based consolidation, particularly in manufacturing-related and diagnostics segments. Key mid-to-large cap deals ($1B-$10B) strengthened with 27 deals totaling $82.6B, while 17 mega-deals ($10B+) reached $26.9B, both showing higher upfront commitments.
Five notable 2025 M&A’s include Johnson & Johnson acquiring Intra-Cellular Therapies for $14.6B (CNS and psychiatric assets), Novartis acquiring Avidity Biosciences for $12B (xRNA platform), Pfizer acquiring Metsera for $7.6B plus $2.4B CVRs (obesity and cardiometabolic pipeline), Merck acquiring Verona Pharma for $10B (COPD therapy Ohtuvayre), and Sanofi acquiring Blueprint Medicines for $9.5B plus $400M milestones (oncology and immunology pipeline). Overall, 2025 underscored a market led by higher-value, strategically significant transactions with stronger pricing and expanded upfront commitments.
In 2025, biopharma therapeutics and platform M&A activity accelerated, with 109 transactions totaling $140.9B, including contingents. A modest increase in deal volume alongside a sharp rise in average deal size to approximately $1.3B. By comparison, 2024 recorded 101 deals valued at $61.8B, equating to about $610M per transaction, highlighting a year dominated by smaller acquisitions. Across 2024 and 2025 combined, the sector completed 210 deals worth $202.7B. The year over year comparison shows deal volume rising 8%, while total transaction value increased 2.3 times, stressing that 2025 growth was driven by larger, more strategic acquisitions.
In 2025, biopharma therapeutics and platform M&A activity strengthened, with 109 deals totaling $119.1B in cash excluding contingents. Average cash consideration per transaction was approximately $1.1B, reflecting a shift toward larger, capital-intensive acquisitions. In contrast, 2024 recorded 101 deals valued at $49.8B in cash, or roughly $490M per deal, indicating a more conservative transaction environment. Across 2024 and 2025 combined, the sector completed 210 deals totaling $168.9B in cash. Year over year, deal volume increased 8%, while total cash value rose 2.4 times, demonstrating that 2025’s recovery was driven primarily by higher transaction values.
In 2025, the average upfront cash and equity consideration in biopharma therapeutics and platforms M&A rose to $1.9B, indicating a shift toward larger commitments at signing. Suggesting a year characterized by higher premiums and strategically driven acquisitions. In 2024, the average upfront stood at $755M, reflecting a cautious environment with smaller initial payments and greater reliance on transaction structure. The increase from $755M to $1.9B represents 2.5 times rise in typical upfront consideration.
In 2025, the median upfront cash and equity consideration in biopharma therapeutics and platforms M&A increased to $591M, indicating a substantially larger upfront commitment than in the prior year. In 2024, the median stood at $250M, reflecting a market where most deals were smaller on an upfront basis. The rise from $250M to $591M, approximately 2.4 times higher, shows that 2025’s improvement was not solely driven by a handful of large transactions inflating averages. Instead, the core of the market shifted upward, pointing to stronger pricing and larger strategic deal sizes across a broader range of transactions.
M&A by Subsector
In 2025, total healthcare and life sciences M&A value increased to $269.3B, driven primarily by Biopharma Therapeutics and Discovery Platforms at $146.8B and a strong rebound in Diagnostics, Sequencing, Omics, and Tools at $74.8B. Together, these segments accounted for most total deal value. Manufacturing Tech and Others remained stable at $30B, while Medtech, Device, Digital Tx, and Wearables totalled $17.8B, indicating fewer large transactions in MedTech relative to other subsectors. In 2024, the total M&A value was $140.8B, with Biopharma at $63.9B and Diagnostics and tools significantly lower at $15.6B. Medtech reached $29.9B, exceeding 2025 levels, while Manufacturing Tech was comparable at $31.4B. Across 2024 and 2025 combined, total deal value reached $410.1B. Year over year, overall M&A value rose 1.9 times in 2025, with growth largely driven by biopharma and diagnostics, while MedTech declined and manufacturing activity remained steady.
In 2025, healthcare and life sciences M&A volume rose to 585 deals, reflecting broad-based expansion across subsectors. Activity was led by Manufacturing Tech and Others with 203 deals, and Diagnostics, Sequencing, Omics, and Tools with 154 deals. Biopharma Therapeutics and Discovery Platforms increased modestly to 136 deals, while Medtech, Device, Digital Tx, and Wearables reached 92 deals. In 2024, the total deal count was 466, with Manufacturing Tech and Others at 144 and Diagnostics and tools at 113, both meaningfully below 2025 levels. Biopharma activity was relatively stable at 134 deals, and Medtech recorded 75 deals. Across 2024 and 2025 combined, the sector completed 1,051 transactions. Year over year, total volume increased 26% in 2025, with the strongest gains in manufacturing-related and diagnostics and tools segments.
Â
Biopharma Therapeutics and Platform M&A – $1B-$10B in Total Value
In 2025, biopharma therapeutics and platform mid to large cap M&A in the $1B to $10B range strengthened, with 27 deals totaling $82.6B, including contingents and $66B on a cash-only basis. This segment carried greater weight than in the prior year, supported by stronger upfront economics. Average upfront cash and equity reached $2.5B, with a median of $1.5B, indicating larger typical commitments at signing. In 2024, deal count was similar at 26 transactions, but total value was lower at $51.8B, including contingents and $41.7B cash-only. Upfront metrics were also more moderate, with a $1.7B average and $1.4B median, pointing to comparable activity levels but less expensive acquisitions. Across 2024 and 2025, this segment accounted for 53 deals totaling $134.4B, including contingents, and $107.8B in cash. Year over year, deal volume was largely unchanged, but transaction values and upfront commitments increased materially in 2025.
Â
Biopharma Therapeutics and Platform M&A – $10B+ in Total Value
In 2025, biopharma therapeutics and platform $10B+ M&A activity accelerated, with 17 mega-deals generating $26.9B in total value, including contingents and $20.7B on a cash-only basis. Upfront economics strengthened meaningfully, with an average upfront of $1.7B and a median of $700M, reflecting larger commitments at signing and more frequent large-scale acquisitions. In 2024, activity was more limited, with 11 deals totaling $7.1B, including contingents and $5.6B cash-only. Upfront metrics were also lower, at an average of $600M and a median of $200M, indicating fewer and less expensive mega-transactions. Across 2024 and 2025, the $10B+ segment accounted for 28 deals totaling $34B, including contingents, and $26.4B in cash.
Prominent Biopharma Therapeutics and Platforms M&A – 2025
Johnson & Johnson acquired Intra-Cellular Therapies – January 2025
Johnson & Johnson agreed to acquire Intra-Cellular Therapies for approximately $14.6B in cash, paying $132 per share, a 40% one-day premium, and completed the deal on April 2, 2025. The acquisition adds approved Caplyta for schizophrenia and other indications, alongside a robust pipeline including phase II lenrispodun (Parkinson’s, heart failure), lumateperone deuterated (anxiety, psychosis), phase I ITI-1020 (oncology), ITI-333 (pain), and preclinical ITI-1500, ITI-1549, and PDE1 inhibitors for CNS disorders. Intra-Cellular will operate as a J&J business unit, strengthening the company’s neurologic, CNS, and cardiovascular portfolio.
Novartis acquiring Avidity Biosciences – October 2025
Novartis announced the acquisition of Avidity Biosciences for approximately $12B ($72 per share in cash, a 46% one-day premium; enterprise value $11B), with completion expected in H1 2026. The deal adds Phase III Delpacibart etedesiran for myotonic dystrophy type 1 and a pipeline including Phase II Del-brax (FSHD), Delpacibart zotadirsen (Duchenne exon 44), and preclinical AOC-145 (Duchenne exon 45), leveraging Avidity’s Antibody Oligonucleotide Conjugates platform to accelerate Novartis’ xRNA strategy. Non-core programs, including AOC-1086 (PLN cardiomyopathy) and AOC-1072 (Prkag2 syndrome), will be spun off into a new entity, SpinCo.
Pfizer acquired Metsera – September 2025
Pfizer announced the acquisition of Metsera, completed on November 13, 2025, for $7.6B in cash ($65.60 per share) plus up to $2.4B in contingent value rights (CVRs) tied to milestones for obesity and cardiometabolic assets, including Phase II MET-097i (weekly/monthly GLP-1 agonist), Phase I MET-233i (amylin analog), and two oral GLP-1 candidates. The deal, structured with additional CVRs and 14.9% of Metsera’s stock previously held by Pfizer, survived a rival Novo Nordisk offer after Metsera deemed it legally and regulatorily risky. The acquisition strengthens Pfizer’s endocrine and metabolic portfolio and advances its next-generation combination therapy pipeline.
Merck acquired Verona Pharma – July 2025
Merck announced the acquisition of Verona Pharma for approximately $10B, paying $107 per ADS (equivalent to $13.375 per ordinary share), completed on October 7, 2025. The deal adds Ohtuvayre (ensifentrine), a dual PDE3/4 inhibitor approved for COPD maintenance and in Phase II for cystic fibrosis, asthma, and non-CF bronchiectasis, along with early-stage combination programs. Verona Pharma will integrate into Merck, expanding its pulmonary and inflammation portfolio.
Sanofi acquired Blueprint Medicines – June 2025
Sanofi announced the acquisition of Blueprint Medicines for $9.5B, paying $129 per share in cash (a 27% one-day premium), with up to $400M in milestone payments tied to clinical and regulatory achievements for BLU-808. Completed on July 18, 2025, the deal adds approved ayvakit for GIST and systemic mastocytosis, Phase III elenestinib, Phase II BLU-808, and a broad discovery pipeline in oncology, breast cancer, mast cell, and protein degrader programs, strengthening Sanofi’s cancer, dermatologic, and inflammatory portfolio.
Also check out Biopharma Therapeutics and Platforms R&D Partnerships – 2025 Review
